Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 7/20 | 0.49 |
| ▸ | FAAH | O00519 | 1/20 | 0.48 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.48 |
| ▸ | CHRNA7 | P36544 | 9/20 | 0.47 |
| ▸ | HTR3E | A5X5Y0 | 5/20 | 0.46 |
| ▸ | HTR3B | O95264 | 5/20 | 0.46 |
| ▸ | HTR3D | Q70Z44 | 5/20 | 0.46 |
| ▸ | HTR3C | Q8WXA8 | 5/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7224475 | 0.90 | KDM1A (0.46) | HTR3AFAAHUSP30CHRNA7HTR3E | |
| SCHEMBL7123407 | 0.88 | USP30 (0.48) | HTR3AFAAHUSP30CHRNA7HTR3E | |
| SCHEMBL7223823 | 0.86 | CHRNA7 (0.50) | HTR3ACHRNA7HTR3EHTR3BHTR3D | |
| SCHEMBL7122580 | 0.85 | CHRNA7 (0.53) | HTR3AFAAHCHRNA7HTR3EHTR3B | |
| SCHEMBL7128786 | 0.85 | HDAC1 (0.51) | HTR3ACHRNA7HTR3EHTR3BHTR3D | |
| SCHEMBL7121773 | 0.85 | CHRNA7 (0.56) | HTR3ACHRNA7HTR3EHTR3BHTR3D | |
| SCHEMBL7114527 | 0.85 | CHRNA7 (0.51) | HTR3ACHRNA7HTR3EHTR3BHTR3D | |
| SCHEMBL7131248 | 0.85 | CHRNA7 (0.52) | HTR3AFAAHCHRNA7HTR3EHTR3B | |
| SCHEMBL373109 | 0.85 | USP30 (0.55) | HTR3AUSP30CHRNA7HTR3EHTR3B | |
| SCHEMBL7119421 | 0.85 | HTR3A (0.50) | HTR3ACHRNA7HTR3EHTR3BHTR3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6599916-B2 | Treating a disease or condition in a mammal, wherein the alpha 7 nicotinic acetylcholine receptor is implicated, Alzheimer's disease, pre-senile dementia (mild cognitive impairment), or senile dementia. | PHARMACIA & UPJOHN COMPANY | 2003-07-29 | — | — | US | claimed |
| US-6500840-B2 | CENTRAL NERVOUS SYSTEM DISORDERS | PHARMACIA & UPJOHN COMPANY | 2002-12-31 | — | — | US | claimed |
| US-6492385-B2 | CENTRAL NERVOUS SYSTEM DISORDERS | PHARMACIA & UPJOHN COMPANY | 2002-12-10 | — | — | US | claimed |
| US-20020091135-A1 | Quinuclidine-substituted heteroaryl moieties for treatment of disease | PHARMACIA & UPJOHN COMPANY GLOBAL INTELLECTUAL PROPERTY | 2002-07-11 | — | — | US | claimed |
| US-20020042428-A1 | Quinuclidine-substituted heteroaryl moieties for treatment of disease | PHARMACIA & UPJOHN COMPANY | 2002-04-11 | — | — | US | claimed |
| US-20020042429-A1 | Quinuclidine-substituted heteroaryl moieties for treatment of disease | PHARMACIA & UPJOHN COMPANY | 2002-04-11 | — | — | US | claimed |
| WO-2002017358-A2 | QUINUCLIDINE-SUBSTITUTED HETEROARYL MOIETIES FOR TREATMENT OF DISEASE (NICOTINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS) | PHARMACIA & UPJOHN COMPANY (US) | 2002-02-28 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020042428-A1 | Quinuclidine-substituted heteroaryl moieties for treatment of disease | NQO2, GBA1, UGT1A1 | HTR3A 712/4885FAAH 1717/4885USP30 3951/4885 |
| US-20020042429-A1 | Quinuclidine-substituted heteroaryl moieties for treatment of disease | PARK7, CYP3A7, UGT2B7 | HTR3A 1069/4885FAAH 2811/4885USP30 3494/4885 |
| US-20020091135-A1 | Quinuclidine-substituted heteroaryl moieties for treatment of disease | NQO2, GBA1, UGT1A1 | HTR3A 712/4885FAAH 1717/4885USP30 3951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.